A process for preparing a deuterated organic compound includes the following steps: a) providing at least one heterogeneous metal catalyst, wherein the providing comprises drying of the metal catalyst; b) preparing a liquid composition comprising at least one organic compound, the at least one heterogeneous metal catalyst, at least one deuterium source, and at least one aliphatic hydrocarbon as solvent, and c) heating the composition to deuterate the organic compound.

A process for preparing a deuterated organic compound includes the following steps: a) providing at least one heterogeneous metal catalyst, wherein the providing comprises drying of the metal catalyst; b) preparing a liquid composition comprising at least one organic compound, the at least one heterogeneous metal catalyst, at least one deuterium source, and at least one aliphatic hydrocarbon as solvent, and c) heating the composition to deuterate the organic compound.

Disclosed is a method for preparing a compound of Formula 1 wherein Q and Z are as defined in the disclosure comprising distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4 wherein M is Ca, Sr or Ba, alkali metal carbonates of Formula 4a wherein M.sup.1 is Li, Na or K, 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water. Also disclosed is a method for preparing a compound of Formula 2 comprising (1) forming a reaction mixture comprising a Grignard reagent derived from contacting a compound of Formula 5 wherein X is Cl, Br or I with magnesium metal or an alkylmagnesium halide in the presence of an ethereal solvent, and then (2) contacting the reaction mixture with a compound of Formula 6 wherein Y is OR.sup.11 or NR.sup.12R.sup.13, and R.sup.11, R.sup.12 and R.sup.13 are as defined in the disclosure. Further disclosed is a method for preparing a compound of Formula 7 wherein Q and Z are as defined in the disclosure, using a compound of Formula 1 characterized by preparing the compound of Formula 1 by the method disclosed above or using a compound of Formula 1 prepared by the method disclosed above. ##STR00001##

A separation medium consisting of a cyclodextrin metal-organic framework (CD-MOF) for separating aromatic compounds and methods of preparing the same are presented. Bottom-up preparations include the following steps: (a) preparing a first mixture comprising a cyclodextrin, an alkali metal salt, water and an alcohol; (b) performing one of the following two steps: (i) stirring the first mixture; or (ii) adding an amount of a surfactant to the first mixture to form a second mixture; and (c) crystallizing the CD-MOF from the first mixture or the second mixture. Top-down preparations include the following steps: (a) preparing a first mixture comprising the cyclodextrin, an alkali metal salt, water and an alcohol; (b) crystallizing the CD-MOF from the first mixture; and (c) optionally performing particle size reduction of the crystallized CD-MOF. The CD-MOFs are amenable for use in methods for separating alkylaromatic and haloaromatic compounds from a mixture of hydrocarbons.

A separation medium consisting of a cyclodextrin metal-organic framework (CD-MOF) for separating aromatic compounds and methods of preparing the same are presented. Bottom-up preparations include the following steps: (a) preparing a first mixture comprising a cyclodextrin, an alkali metal salt, water and an alcohol; (b) performing one of the following two steps: (i) stirring the first mixture; or (ii) adding an amount of a surfactant to the first mixture to form a second mixture; and (c) crystallizing the CD-MOF from the first mixture or the second mixture. Top-down preparations include the following steps: (a) preparing a first mixture comprising the cyclodextrin, an alkali metal salt, water and an alcohol; (b) crystallizing the CD-MOF from the first mixture; and (c) optionally performing particle size reduction of the crystallized CD-MOF. The CD-MOFs are amenable for use in methods for separating alkylaromatic and haloaromatic compounds from a mixture of hydrocarbons.

A substituted alkenylbenzene compound of formula (4):

##STR00001##

wherein X.sup.1 is selected from the group consisting of halogen atom, SF.sub.5, C.sub.1-C.sub.6halo alkyl, hydroxy C.sub.1-C.sub.6haloalkyl, C.sub.1-C.sub.6alkoxy C.sub.1-C.sub.6haloalkyl, C.sub.3-C.sub.8halocycloalkyl, C.sub.1-C.sub.6 haloalkoxy, C.sub.1-C.sub.3haloalkoxy C.sub.1-C.sub.3haloalkoxy, C.sub.1-C.sub.6haloalkylthio, C.sub.1-C.sub.6haloalkylsulfinyl and C.sub.1-C.sub.6haloalkylsulfonyl; X.sup.3 is selected from the group consisting of a hydrogen atom, halogen atom, cyano, nitro, C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl, C.sub.1-C.sub.6alkoxy and C.sub.1-C.sub.6 alkylthio; X.sup.4 is selected from the group consisting of a hydrogen atom, halogen atom, cyano, C.sub.1-C.sub.4alkyl, C.sub.1-C.sub.4alkoxy and C.sub.1-C.sub.4haloalkoxy; R.sup.3 is C(R.sup.3a)(R.sup.3b)R.sup.3c, where R.sup.3a and R.sup.3b independently of each other are a halogen atom, or R.sup.3a and R.sup.3b together form 3- to 6-membered ring together with the carbon atom bonding them by forming a C.sub.2-C.sub.5haloalkylene chain, and R.sup.3c is selected from the group consisting of a hydrogen atom, halogen atom, C.sub.1-C.sub.5alkyl, C.sub.1-C.sub.5haloalkyl, C.sub.1-C.sub.4haloalkoxy and C.sub.1-C.sub.4haloalkylthio, with a proviso that in case where X.sup.1 is a fluorine atom, chlorine atom or trifluoromethyl, and both X.sup.2 and X.sup.3 are a hydrogen atom, in case where both X.sup.1 and X.sup.2 are fluorine atom and X.sup.3 is a hydrogen atom, and in case where both X.sup.1 and X.sup.2 are trifluoromethyl and X.sup.3 is a hydrogen atom, R.sup.3c is a hydrogen atom, chlorine atom, bromine atom, iodine atom, C.sub.1-C.sub.5alkyl, C.sub.1-C.sub.5haloalkyl, C.sub.1-C.sub.4haloalkoxy or C.sub.1-C.sub.4haloalkylthio.

Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.